Axial Spondyloarthritis/Ankylosing Spondylitis Trials
The Division of Rheumatology strives to understand more about Spondyloarthritis through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
| Program for individuals with an Elevated Risk of Spondyloarthritis (PIERS) 17-0977 Liron Caplan, MD | Long-term research study of individuals at risk of spondyloarthritis (SpA). This study does not include a placebo group. | 1) Parent, child, or sibling (by blood) of someone with spondyloarthritis 2) Individuals with SpA or SpA associated conditions such as inflammatory bowel disease, psoriasis, or uveitis) | 303-724-3539 or email Andrew Stahly |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individual’s eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.